Want to see ES:ECR full AI Analyst Report?
ECR Stock Chart & Stats
€3.43
€0.00(0.00%)
At close: 4:00 PM EST
€3.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.23 - €3.49
Previous CloseN/A
Volume8.56K
Average Volume (3M)68.83K
Market Cap
€317.74M
Enterprise Value€440.20
Total Cash (Recent Filing)€45.41M
Total Debt (Recent Filing)€213.99M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.27%
Share Statistics
EPS (TTM)-0.74
Shares Outstanding91,436,195
10 Day Avg. Volume92,838
30 Day Avg. Volume68,826
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)0.50
P/FCF Ratio15.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€662.80M
Bulls Say, Bears Say
Bulls Say
Cash Generation AbilityErcros has demonstrated the ability to convert operations into cash, with positive operating and free cash flow in 2025 and historically strong cash in 2020–2023. Durable cash conversion supports working capital, capex and debt servicing even if earnings remain volatile.
Moderate Leverage CushionAlthough leverage increased, debt remains below equity in 2025, providing a capital cushion. This structural capital position preserves financial flexibility for restructuring, incremental investment or temporary demand shocks relative to highly leveraged peers.
Industrial B2B Business ModelErcros’s core model — manufacturing basic chemicals for industrial customers under supply contracts — yields predictable demand patterns, fixed-cost absorption via utilization, and potential for price pass-through of raw-material and energy costs, supporting steadier long-term cash flow.
Bears Say
Profitability DeteriorationThe company shifted from healthy profits to sustained losses through 2024–2025, with revenue trending down since the 2022 peak. Persistent margin compression and losses weaken reinvestment capacity, long-term competitiveness and raise the risk of structural earnings impairment.
Weakening Balance Sheet TrendRising leverage and falling equity reduce the firm’s solvency buffer and limit strategic options. Over time this increases refinancing and covenant risk, elevates borrowing costs, and constrains the ability to fund capex or weather cyclical downturns without external support.
Volatile Cash FlowsWhile cash generation can be strong, swings from negative FCF in 2024 to positive in 2025 show inconsistency. Such volatility complicates capital planning, increases reliance on short-term financing, and undermines confidence in sustained funding for growth or deleveraging.
Ercros SA News
ECR FAQ
What was Ercros SA’s price range in the past 12 months?
Ercros SA lowest stock price was €2.23 and its highest was €3.49 in the past 12 months.
What is Ercros SA’s market cap?
Ercros SA’s market cap is €317.74M.
When is Ercros SA’s upcoming earnings report date?
Ercros SA’s upcoming earnings report date is Jul 29, 2026 which is in 4 days.
How were Ercros SA’s earnings last quarter?
Ercros SA released its earnings results on May 20, 2026. The company reported -€0.266 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ercros SA overvalued?
According to Wall Street analysts Ercros SA’s price is currently Overvalued.
Does Ercros SA pay dividends?
Ercros SA pays a Annually dividend of €0.096 which represents an annual dividend yield of 2.27%. See more information on Ercros SA dividends here
What is Ercros SA’s EPS estimate?
Ercros SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ercros SA have?
Ercros SA has 91,436,195 shares outstanding.
What happened to Ercros SA’s price movement after its last earnings report?
Ercros SA reported an EPS of -€0.266 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.146%.
Which hedge fund is a major shareholder of Ercros SA?
Currently, no hedge funds are holding shares in ES:ECR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ercros SA
Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.
Technical Analysis
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Repsol
―





